Interim results from a phase 2 investigator-initiated study of domvanalimab, a Fc-silent anti-TIGIT mAb, and zimberelimab, an anti-PD-1 mAb, in patients with anti-PD-1/PD-L1 refractory HCC showed that among the 29 evaluable patients, the confirmed ORR was 17.2%, including one complete response, and mPFS was 4.4 months [90]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.